We are international
#Ask Dr. Durie



Have a question? Submit it to AskDrDurie@myeloma.org!


We take questions every week - all are important, however Dr. Durie can only answer so many... so email us - as well as connect with us via one of the social media channels listed above - and we will get it to Dr. Durie!

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!




#Ask Dr. Durie
    next      view all

01.22.15   If bone density is low, does that mean myeloma is present?

In this week's episode of #AskDrDurie, IMF Chairman Dr. Brian Durie answers a patient's question about levels of bone density and how they connect to myeloma.

01.15.15   What is the 17p deletion?

In this week’s episode of #AskDrDurie Dr. Brian Durie discusses the importance of the 17p deletion chromosome abnormality when remission has been achieved.

01.08.15   #AskDrDurie: What’s new with the Black Swan Research Initiative®?

In the first episode of the new year, Dr. Brian Durie of the IMF looks back on the progress of a signature project, the Black Swan Research Initiative® to discuss major accomplishments in 2014.

12.18.14   #AskDrDurie: What does IMWG’s new diagnostic criteria mean for myeloma patients?

In this episode of #AskDrDurie, Dr. Brian Durie talks about the new diagnostic guidelines and tests that can be used to diagnose myeloma early, before CRAB features have emerged. These criteria have been published in a new publication available on myeloma.org.

12.10.14   #AskDrDurie: Why wasn’t panobinostat approved?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a  patient's question about why the recent FDA ODAC hearing rejected the use of new drug panobinostat for myeloma. He also discusses other HDAC inhibitors that are currently in development.

12.03.14   #AskDrDurie: What's new at ASH 2014

In this week’s special #AskDrDurie episode, Dr. Brian Durie of the IMF takes a look at the December 2014 ASH (American Society of Hematology) meeting in San Francisco. He previews what abstracts will be presented and talks about news to expect out of the meeting.

11.19.14   #AskDrDurie: Can Cytoxan cause heart damage?

In this week's #AskDrDurie, the IMF's Dr. Brian G.M. Durie answers a patient's concern regarding myeloma treatment and heart damage--specifically when it comes to the drug Cytoxan.

11.13.14   #AskDrDurie: What happens to stem cells once they are harvested?

In this week's episode of #AskDrDurie, Dr. Brian G.M. Durie of the IMF answers a patient's question regarding stem cells. If they are harvested in a specific facility, can they be moved and stored elsewhere later?
Find out the answer in this video!

11.06.14   #AskDrDurie: Can the Hevylite™ test be used to monitor IgA myeloma?

In this week’s episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a patient question regarding IgA myeloma and tests used to monitor it, specifically the Hevylite™ test. Watch this video to learn all about Hevylite.

10.30.14   #AskDrDurie: Is it possible to have short remissions without high-risk features?

Inspired by last week's #AskDrDurie episode in which Dr. Brian Durie of the IMF explained the definition of remission when it comes to  myeloma patients, this new episodes is a follow-up. Here, Dr. Durie explains why a myeloma patient might experience a short remission period, even if high-risk features have not been identified.

    next      view all